Selected article for: "infectious period and new infection"
Author: Huang, Boxuan; Ling, Rongsong; Cheng, Yifan; Wen, Jieqi; Dai, Yarong; Huang, Wenjie; Zhang, Siyan; Lu, Xifeng; Luo, Yifeng; Jiang, Yi-Zhou
Title: Characteristics and Therapeutic Options of the Coronavirus Disease 2019
  • Cord-id: b69zgnku
  • Document date: 2020_6_24
    • ID: b69zgnku
    Snippet: Abstract The Coronavirus Disease 2019 (COVID-19) is a new type of pneumonia caused by SARS-CoV-2 infection. COVID-19 is affecting millions of patients and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problem all over the world. Currently there is no effective proven drugs for the treatment of COVID-19, therefore, development of effective therapeutic drugs to suppress SARS-C
    Document: Abstract The Coronavirus Disease 2019 (COVID-19) is a new type of pneumonia caused by SARS-CoV-2 infection. COVID-19 is affecting millions of patients and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problem all over the world. Currently there is no effective proven drugs for the treatment of COVID-19, therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2, and introduce its infection and replication process. Then we review the clinical symptoms, diagnosis and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acid detection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid detection and lopinavir ritonavir: 1, 2, 3
    • acid detection and lung image: 1, 2, 3
    • acquire immunity and acute respiratory syndrome: 1, 2, 3, 4
    • acute pneumonia and ade antibody dependent enhancement: 1, 2
    • acute pneumonia and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute pneumonia and lung cavitation: 1, 2, 3
    • acute respiratory syndrome and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long term important: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir compare: 1
    • acute respiratory syndrome and lung cavitation: 1, 2
    • long term important and lopinavir ritonavir: 1